CONFLICT OF INTEREST STATEMENT
ONCOLOGY
Dae Ho Lee: Personal fees: AbbVie, AstraZeneca, BC Pharma, Boehringer Ingelheim, Bristol‐Myers Squibb, ChongKeunDang, CJ Healthcare, Eli Lilly, Genexine, Janssen, Menarini, Merck, MSD, Mundipharma, Novartis, ONO, Pfizer, Roche, Samyang Biopharm, ST Cube, Takeda. Non‐financial support: Blueprint Medicines, Takeda. Hye Ryun Kim: Consultant/advisor: AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, MSD, Takeda. Honoraria: AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, MSD, ONO. Research funding: AstraZeneca, Bristol‐Myers Squibb, ONO, YUHAN. Bhumsuk Keam: Research funding: AstraZeneca, MSD Oncology, ONO. Consultant/advisor: ABL Bio, AstraZeneca, CbsBioscience, Cellid, Genexine, Handok, MSD Oncology. Honoraria: AstraZeneca, Merck, MSD Oncology. Ken Kato: Research funding: AstraZeneca, Bayer, BeiGene, Chugai, Merck, Merck Serono, MSD, Oncolys BioPharma, ONO, Shionogi. Yasutoshi Kuboki: Research funding: Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi‐Sankyo, Genmab, GSK, Incyte, Lilly, ONO, Taiho, Takeda. Honoraria: Bayer, Bristol‐Myers Squibb, Lilly, Merck Serono, ONO, Taiho. Haiyan Gao, Alejandro Yovine, and Scott H. Robbins: Employees/shareholders: AstraZeneca. Myung‐Ju Ahn: Consultant/advisor: Alpha Pharmaceutical, AstraZeneca, Bristol‐Myers Squibb, MSD, Novartis, Roche, Takeda. Honoraria: AstraZeneca, Bristol‐Myers Squibb, MSD, ONO, Roche.